Drug Trial Radar · NCT02028676
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
Last checked: Nov 19, 2026Latest source record: Jun 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,206
Actual
Start
Mar 2007
Primary completion
Mar 2012
Study completion Jun 2012
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- Department for International Development, United Kingdom; ViiV Healthcare; GlaxoSmithKline
- First posted
- Jan 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The two original objectives were to determine in HIV-infected children initiating antiretroviral therapy (ART): 1. Whether clinically driven monitoring (CDM) will have a similar outcome in terms of disease progression or death as routine laboratory and clinical monitoring (LCM) for toxicity (haematology/biochemistry) and efficacy (CD4)? 2. Whether induction with four drugs from two ART classes followed by maintenance with three drugs after 36 weeks be more effective than a continuous non-nucleoside reverse transcriptase inhibitors (NNRTI)-based triple drug regimen in terms of CD4 and clinical outcome? Two secondary objectives were to determine 3. Whether changing from twice daily lamivudine+abacavir to once daily lamivudine+abacavir after 48 weeks on ART will have a similar outcome in terms of virological suppression and will result in improvements in adherence to ART? 4. Whether stopping daily cotrimoxazole prophylaxis in children over 3 years of age who have been on ART for at least 96 weeks has a similar outcome in terms of hospitalisation or death as continuing daily cotrimoxazole?
Conditions
- Human Immunodeficiency Virus
Interventions
Clinically Driven Monitoring (CDM)Other
Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
Laboratory plus Clinical Monitoring (LCM)Other
Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
Arm A: ABC+3TC+NNRTIDrug
Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenanceDrug
Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenanceDrug
Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
Once-daily ABC+3TCDrug
Twice-daily ABC+3TCDrug
Continued cotrimoxazole prophylaxisDrug
Stopped cotrimoxazole prophylaxisOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or DeathTime frame: Median 4 years (from randomization to 16 March 2012; maximum 5 years)
- LCM vs CDM: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIVTime frame: Median 4 years (from randomization to 16 March 2012; maximum 5 years)
- Induction ART: Change From Baseline in CD4% 72 Weeks After ART InitiationTime frame: Baseline, 72 weeks
- Induction ART: Change From Baseline in CD4% to 144 Weeks From ART InitiationTime frame: Baseline, 144 weeks
- Induction ART: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIVTime frame: Median 4 years (from randomization to 16 March 2012; maximum 5 years)
- Once Versus Twice Daily Abacavir+Lamivudine: Suppressed HIV RNA Viral Load 48 Weeks After RandomisationTime frame: 48 weeks
- Once Versus Twice Daily Abacavir+Lamivudine: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIV, Judged Definitely/Probably or Uncertain Whether Related to Lamivudine or AbacavirTime frame: Median 2 years (from once vs twice daily randomization to 16 March 2012; maximum 2.6 years)
- Cotrimoxazole: New Hospitalisation or DeathTime frame: Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)
- Cotrimoxazole: New Grade 3 or 4 Adverse Event (AE), Not Solely Related to HIVTime frame: Median 2 years (from cotrimoxazole randomization to 16 March 2012; maximum 2.5 years)
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
MRC /UVRI Uganda Research Unit on AIDS
Entebbe, Uganda
Joint Clinical Research Centre
Kampala, Uganda
Baylor College of Medicine Children's Foundation
Mulago, Uganda
University of Zimbabwe Medical School
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.